Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Are Wall Street Analysts Bullish on Biogen Stock?

May 20, 2026 at 08:35 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies in the United States and internationally. The company has a market cap of $28.1 billion and focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, and others.

BIIB shares have rallied the broader market over the past year, surged 47.2% compared to the S&P 500 Index ($SPX) 23.3% surge. Moreover, in 2026, the stock has grown nearly 8.3%, outperforming the SPX’s 7.4% rise as well.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

Focusing on its industry benchmark, the State Street Healthcare Select Sector SPDR ETF (XLV) has risen 9.6% over the past year, underperforming the stock. In 2026, XLV has declined 4.8% and has also lagged behind the stock.

On Apr. 29, BIIB stock rose 6% following the release of its better-than-expected Q1 2026 earnings. The company’s revenue rose 1.9% from the prior year’s quarter to $2.5 billion and surpassed the Street’s estimates. Moreover, its adjusted EPS came in at $3.57, also coming in on top of Wall Street’s forecasts.

For the current year, which ends in December, analysts expect BIIB’s EPS to fall 7.2% to $14.18 on a diluted basis. The company surpassed the consensus estimate in each of the last four quarters.

Among the 35 analysts covering BIIB stock, the consensus is a “Moderate Buy.” That’s based on 18 “Strong Buy” ratings, one “Moderate Buy,” and 16 “Holds.”

The configuration has become much more bullish over the past month.

On May 15, Evercore ISI analyst Umer Raffat reinstated an “Outperform” rating for Biogen. The report did not include any revisions to the price targets.

BIIB’s mean price target of $218.97 indicates a premium of 14.9% from the current market prices. Its Street-high target of $300 suggests a robust 57.4% upside potential from current price levels.

On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article